about   CII home   shop   checkout


Current Event 

Day 1 
Day 2 
Day 3 
Short Courses
Hotel & Travel
Download Brochure
Sponsor & Exhibit 
Press Pass

 Alliance Management and Business Development Network

4,700+ alliance
leaders strong

Presenting Companies 


Acorda Therapeutics
Bayer HealthCare
Biogen Idec
Daiichi Sankyo
Emergent Biosolutions
Integrated Project Management
Janssen Diagnostics
Johnson & Johnson
Merck & Co.
Merck Sharp & Dohme Corp
Novartis Oncology
Osage University Partners
Partners HealthCare
PortaScience, Inc.
Princeton Univ
The Children's Hospital of Philadelphia
Threshold Pharmaceuticals
University of Pennsylvania
Vantage Partners

Short Courses

Archived Content


Pre-Conference Short Course* 

Monday, May 6 • 9:00am – 12:00pm

Vantage PartnersSC1: Alliance Manager as Interventionist: A Critical Role and Skill Set

Instructor: Renee Jansen, J.D., Principal, Vantage Partners

Alliance managers often compare themselves to firefighters because they get called in when things go wrong, get out of control, or those in the middle of some kind of conflagration feel that outside assistance would be helpful. To that end, alliance managers need to understand that a big part of their role is that of "interventionist" – the individual who can step in, quickly assess and understand a situation, and then intervene based on a clear theory and/or methodology for how to take the situation from raging or out of control, to one of joint problem solving and, ultimately, on the merits resolution. If they cannot, a failed intervention can often make the situation worse.This short course, hosted by Vantage Partners, will provide participants with clarity about what good intervention looks like and how alliance managers can become effective interventionists. Participants will learn:

  • A methodology for defining intervention success
  • Key tools that an effective interventionist employs
  • A process for mapping out a planned intervention 
Podcast Icon

The Evolution of Alliance Management:
Perspective Over a Decade, Current Challenges, and Outlook




9:00am Opening Remarks

9:05 Discussion on What it Means to be An Alliance Interventionist: The Situations that Require Intervention and the Skills that are Needed to Support Effective Intervention

- Define the elements of a good outcome of an alliance intervention
- Share a model for joint problem solving that sits at the core of the intervention process

10:15 Networking Coffee Break

10:35 Review Additional Tools and Frameworks for Effective Alliance Intervention

- Building understanding while in difficult conversations
- Transforming a conversation that is focused on blame
- Building a durable multi-party agreement
- Diagnosing and planning for solutions in complex situations

Discussion on How these Tools Might be Applied in an Issue that Requires Intervention

12:00 End of Short Course



Dinner Short Course* 

Tuesday, May 7 • 5:30 – 8:30pm

SC2: Stratified Medicines:  Rx and CDx Opportunities for Patients, Producers and Providers

Instructor: Mark Trusheim, Executive in Residence & Visiting Scientist at MIT; Former, Special Government Employee at Office of the Commissioner, FDA

By actively exploiting variable patient responses to therapeutics by using companion diagnostics to target those most likely to benefit, stratified medicines are profoundly affecting decades old clinical development strategies, partnering business models, regulatory paradigms, clinical practices and innovator profitability.  This short course will examine all these key areas simultaneously, drawing on recently published quantitative analyses by a public/private consortium, to describe an emerging framework that suggests commercial strategies and reimbursement, not science alone, will create conditions for either continued Pharmageddon, or for a renewed virtuous cycle of medical miracles for patients, payers and innovators.


5:30 Introductions and Objectives 

5:45 Stratified Medicine Dynamics & Opportunities
  • Framework and foundation concepts for Stratified Medicines: Full therapeutic life cycle from multiple stakeholder perspectives 
  • Class participation case study in a neurodegenerative indication 
  • Managing the Rx-CDx development tensions 
  • Conclusion and take-home messages 
  • Q & A session 

6:50 Networking Dinner Break 

7:10 Beyond Science: Navigating Policy, Payers and Business Models
  • The breadth of successful examples: Balancing principles and specific circumstances 
  • Finding the economically feasible space: from business models to clinical utility to policy issues & back again  
  • Back to the Future: Impact of Accountable Care Organizations, PDUFA and patient advocacy/disease foundation 
  • Q & A session 
8:20 Short Course Wrap-Up

8:30 End of Short Course

* Separate registration required